Drug Safety

, Volume 23, Issue 5, pp 449–461

Risks and Benefits of Preoperative High Dose Methylprednisolone in Surgical Patients

A Systematic Review
  • Stefan Sauerland
  • Manfred Nagelschmidt
  • Peter Mallmann
  • Edmund A. M. Neugebauer
Original Research Article

Abstract

Background: A single preoperative high dose of methylprednisolone (15 to 30 mg/kg) has been advocated in surgery, because it may inhibit the surgical stress response and thereby improve postoperative outcome and convalescence. However, these potential clinical benefits must be weighed against possible adverse effects.

Objective: To conduct a risk-benefit analysis using a meta-analysis, to compare complication rates and clinical advantages associated with the use of high dose methylprednisolone in surgical patients.

Methods: Randomised controlled trials of high dose methylprednisolone in elective and trauma surgery were systematically searched for in various literature databases. Outcome data on adverse effects, postoperative pain and hospital stay were extracted and statistically pooled in fixed-effects meta-analyses.

Results: We located 51 studies in elective cardiac and noncardiac surgery, aswell as traumatology. Pooled data failed to show any significant increase in complication rates. In patients treated with corticosteroids, nonsignificantly more gastrointestinal bleeding and wound complications were observed; the 95% confidence interval boundaries of the numbers-needed-to-harm were 59 and 38, respectively. The only significant finding was a reduction of pulmonary complications (risk difference −3.5%; 95% confidence interval −1.0 to −6.1), mainly in trauma patients.

Conclusion: For patients undergoing surgical procedures, a perioperative single-shot administration of high dose methylprednisolone is not associated with a significant increase in the incidence of adverse effects. In patients with multiple fractures, limited evidence suggests promising benefits of glucocorticoids on pulmonary complications.

References

  1. 1.
    Walsh LJ, Wong CA, Pringle M, et al. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996; 313: 344–6PubMedGoogle Scholar
  2. 2.
    Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol 1972; 13: 694–8Google Scholar
  3. 3.
    Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11: 954–63PubMedGoogle Scholar
  4. 4.
    Messer J, Reitman D, Sacks HS, et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983; 309: 21–4PubMedGoogle Scholar
  5. 5.
    Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994; 236: 619–32PubMedGoogle Scholar
  6. 6.
    Robbins JJ. Steroid side effects, a credibility gap between fact and opinion [letter]. N Engl J Med 1968; 279: 328PubMedGoogle Scholar
  7. 7.
    Tuft L. “Steroid-phobia” in asthma management. Ann Allergy 1979; 42: 152–9PubMedGoogle Scholar
  8. 8.
    Cronstein BN, Kimmel SC, Levin RI, et al. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci USA 1992; 89: 9991–5PubMedGoogle Scholar
  9. 9.
    Weiler JM, Packard BD. Methylprednisolone inhibits the alternative and amplification pathways of complement. Infect Immun 1982; 38: 122–6PubMedGoogle Scholar
  10. 10.
    Buttgereit F, Dimmeler S, Neugebauer E, et al. Mechanisms of action of high-dosage glucocorticoid therapy [in German]. Dtsch Med Wochenschr 1996; 121: 248–52PubMedGoogle Scholar
  11. 11.
    Hall ED. The neuroprotective pharmacology of methylprednisolone. J Neurosurg 1992; 76: 13–22PubMedGoogle Scholar
  12. 12.
    Munck A, Naray-Fejes-Toth A. Glucocorticoids and stress: permissive and suppressive actions. Ann NY Acad Sci 1994; 746: 115–30PubMedGoogle Scholar
  13. 13.
    Lipworth BJ. Therapeutic implications of non-genomic glucocorticoid activity. Lancet 2000; 356: 87–9PubMedGoogle Scholar
  14. 14.
    Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990; 322: 1405–11PubMedGoogle Scholar
  15. 15.
    Bracken MB, Shepard MJ, Collins WF, Jr., et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study. J Neurosurg 1992; 76: 23–31PubMedGoogle Scholar
  16. 16.
    Bracken MB. Pharmacological interventions for acute spinal cord injury [Cochrane Review]. In: Cochrane Collaboration, editor. The Cochrane Library, Issue 1/2000 [CD-ROM]. Oxford/UK: Update Software, 2000Google Scholar
  17. 17.
    Alderson P, Roberts I. Corticosteroids in acute traumatic brain injury [Cochrane Review]. In: Cochrane Collaboration, editor. The Cochrane Library, Issue 1/2000 [CD-ROM]. Oxford/UK: Update Software, 2000Google Scholar
  18. 18.
    Dietzman RH, Lunseth JB, Goott B, et al. The use of methylprednisolone during cardiopulmonary bypass. A review of 427 cases. J Thorac Cardiovasc Surg 1975; 69: 870–3PubMedGoogle Scholar
  19. 19.
    Rokkanen P, Alho A, Avikainen V, et al. The efficacy of corticosteroids in severe trauma. Surg Gynecol Obstet 1974; 138: 69–73PubMedGoogle Scholar
  20. 20.
    Svennevig JL, Bugge-Asperheim B, Bjorgo S, et al. Methylprednisolone in the treatment of lung contusion following blunt chest trauma. Scand J Thorac Cardiovasc Surg 1980; 14: 301–5PubMedGoogle Scholar
  21. 21.
    Tonnesen E, Wanscher M, Hohndorf K, et al. Effect of methylprednisolone on the cytokine response in patients undergoing lung surgery. Acta Anaesthesiol Scand 1993; 37: 410–4PubMedGoogle Scholar
  22. 22.
    Schulze S, Moller IW, Bang U, et al. Effect of combined prednisolone, epidural analgesia and indomethacin on pain, systemic response and convalescence after cholecystectomy. Acta Chir Scand 1990; 156: 203–9PubMedGoogle Scholar
  23. 23.
    Høgevold HE, Aasen AO, Kierulf P, et al. High doses of corticosteroids in total hip replacement. Effects on components of coagulation, fibrinolytic, plasma kallikrein-kinin and complement systems. Acta Chir Scand 1989; 155: 247–50PubMedGoogle Scholar
  24. 24.
    Hammerschmidt DE, White JG, Craddock PR, et al. Corticosteroids inhibit complement-induced granulocyte aggregation. A possible mechanism for their efficacy in shock states. J Clin Invest 1979; 63: 798–803PubMedGoogle Scholar
  25. 25.
    Barber AE, Coyle SM, Fischer E, et al. Influence of hypercortisolemia on soluble tumor necrosis factor receptor II and interleukin-1 receptor antagonist responses to endotoxin in human beings. Surgery 1995; 118: 406–11PubMedGoogle Scholar
  26. 26.
    Moore PK, Hoult JR. Anti-inflammatory steroids reduce tissue PG synthetase activity and enhance PG breakdown. Nature 1980; 288: 269–70PubMedGoogle Scholar
  27. 27.
    Korman B, McKay RJ. Steroids and postoperative analgesia. Anaesth Intens Care 1985; 13: 395–8Google Scholar
  28. 28.
    Neugebauer E, Dietrich A, Bouillon B, et al. Steroids in trauma patients-right or wrong? A qualitative meta-analysis of clinical studies. Theor Surg 1990; 5: 44–53Google Scholar
  29. 29.
    Beckmann J. Basic aspects of risk-benefit analysis. Semin Thromb Hemost 1999; 25: 89–95PubMedGoogle Scholar
  30. 30.
    Edwards R, Wiholm BE, Martinez C. Concepts in risk-benefit assessment. A simple merit analysis of a medicine? Drug Saf 1996; 15: 1–7PubMedGoogle Scholar
  31. 31.
    Krantz T, Wolff C, Hjortso NC, et al. Assessment of early postoperative convalescence by a simple scoring system [in Danish]. Ugeskr Laeger 1990; 152: 1168–70PubMedGoogle Scholar
  32. 32.
    Bigler D, Jonsson T, Olsen J, et al. The effect of preoperative methylprednisolone on pulmonary function and pain after lung operations. J Thorac Cardiovasc Surg 1996; 112: 142–5PubMedGoogle Scholar
  33. 33.
    Komori K, Ishida M, Matsumoto T, et al. Cytokine patterns and the effects of a preoperative steroid treatment in the patients with abdominal aortic aneurysms. Int Angiol 1999; 18: 193–7PubMedGoogle Scholar
  34. 34.
    Launo C, Palermo S, Gobbi GC, et al. Methylprednisolone sodium succinate versus placebo in the prevention of respiratory complications after thoracic surgery [In Italian]. Minerva Anestesiol 1990; 56: 219–23PubMedGoogle Scholar
  35. 35.
    Nagelschmidt M, Fu ZX, Saad S, et al. Preoperative high dose methylprednisolone improves patients outcome after abdominal surgery. Eur J Surg 1999; 165: 971–8PubMedGoogle Scholar
  36. 36.
    Schulze S, Andersen J, Overgaard H, et al. Effect of prednisolone on the systemic response and wound healing after colonic surgery. Arch Surg 1997; 132: 129–35PubMedGoogle Scholar
  37. 37.
    Sumida M, Inaba H, Isawa E, et al. Prevention by methylprednisolone of increased circulating tumor necrosis factor-alpha levels and lung injury associated with systemic inflammatory response syndrome due to intraperitoneal hyperthermia. Anesth Analg 1999; 88: 771–6PubMedGoogle Scholar
  38. 38.
    Takeda S, Ogawa R, Nakanishi K, et al. The effect of preoperative high dose methylprednisolone in attenuating the metabolic response after oesophageal resection. Eur J Surg 1997; 163: 511–7PubMedGoogle Scholar
  39. 39.
    Zotti GC, Salzano de Luna F, Caiazza A, et al. Prevention of pulmonary complications by 6-methylprednisolone in major abdominal surgery. Ital J Surg Sci 1988; 18: 369–75PubMedGoogle Scholar
  40. 40.
    Chaney MA, Nikolov MP, Blakeman B, et al. Pulmonary effects of methylprednisolone in patients undergoing coronary artery bypass grafting and early tracheal extubation. Anesth Analg 1998; 87: 27–33PubMedGoogle Scholar
  41. 41.
    Chaney MA, Nikolov MP, Blakeman BP, et al. Hemodynamic effects of methylprednisolone in patients undergoing cardiac operation and early extubation. Ann Thorac Surg 1999; 67: 1006–11PubMedGoogle Scholar
  42. 42.
    Engelman RM, Rousou JA, Flack JE, 3rd, et al. Influence of steroids on complement and cytokine generation after cardiopulmonary bypass. Ann Thorac Surg 1995; 60: 801–4PubMedGoogle Scholar
  43. 43.
    Fecht DC, Magovern GJ, Park SB, et al. Beneficial effects of methylprednisolone in patients on cardiopulmonary bypass. Circ Shock 1978; 5: 415–22PubMedGoogle Scholar
  44. 44.
    Niazi Z, Flodin P, Joyce L, et al. Effects of glucocorticosteroids in patients undergoing coronary artery bypass surgery. Chest 1979; 76: 262–8PubMedGoogle Scholar
  45. 45.
    Tassani P, Richter JA, Barankay A, et al. Does high-dose methylprednisolone in aprotinin-treated patients attenuate the systemic inflammatory response during coronary artery bypass grafting procedures? J Cardiothorac Vasc Anesth 1999; 13: 165–72PubMedGoogle Scholar
  46. 46.
    Otani K, Abe H, Kadoya S, et al. Beneficial effect of methylprednisolone sodium succinate in the treatment of acute spinal cord injury [In Japanese]. Spine and Spinal Cord 1994; 7: 633–47Google Scholar
  47. 47.
    Otani K. Treatment effect of methylprednisolone sodium succinate in acute cervical spinal cord injury [in Japanese]. J Jpn Med Soc Parapl 1995; 8: 80–1Google Scholar
  48. 48.
    Petitjean ME, Pointillart V, Dixmerias F, et al. Pharmacological therapy of spinal cord injury at the acute phase [In French]. Ann Fr Anesth Reanim 1998; 17: 114–22PubMedGoogle Scholar
  49. 49.
    Pointillart V, Petitjean ME, Wiart L, et al. Pharmacological therapy of spinal cord injury during the acute phase. Spinal Cord 2000; 38: 71–6PubMedGoogle Scholar
  50. 50.
    Pettersson K, Toolanen G. High-dose methylprednisolone prevents extensive sick leave after whiplash injury. A prospective, randomized, double-blind study. Spine 1998; 23: 984–9PubMedGoogle Scholar
  51. 51.
    Høgevold HE, Hoiseth A, Reikerås O. Effect of high-dose corticosteroids on the incidence of deep vein thrombosis after total hip replacement. Arch Orthop Trauma Surg 1991; 111: 29–31PubMedGoogle Scholar
  52. 52.
    Høgevold HE, Mundal HH, Norman N, et al. Platelet release reaction and plasma catecholamines during total hip replacement. No effects of high doses of corticosteroids. Thromb Res 1990; 57: 21–9PubMedGoogle Scholar
  53. 53.
    Gammer W, Bengtson A, Heideman M. Inhibition of complement activation by high-dose corticosteroids in total hip arthroplasty. Clin Orthop 1988; 236: 205–9PubMedGoogle Scholar
  54. 54.
    Andersen LW, Baek L, Thomsen BS, et al. Effect of methylprednisolone on endotoxemia and complement activation during cardiac surgery. J Cardiothorac Anesth 1989; 3: 544–9PubMedGoogle Scholar
  55. 55.
    Jansen NJ, van Oeveren W, van Vliet M, et al. The role of different types of corticosteroids on the inflammatory mediators in cardiopulmonary bypass. Eur J Cardiothorac Surg 1991; 5: 211–7PubMedGoogle Scholar
  56. 56.
    Mayumi H, Zhang QW, Nakashima A, et al. Synergistic immuno-suppression caused by high-dose methylprednisolone and cardiopulmonary bypass. Ann Thorac Surg 1997; 63: 129–37PubMedGoogle Scholar
  57. 57.
    Morton JR, Hiebert CA, Lutes CA, et al. Effect of methylprednisolone on myocardial preservation during coronary artery surgery. Am J Surg 1976; 131: 419–22PubMedGoogle Scholar
  58. 58.
    Toft P, Christiansen K, Tonnesen E, et al. Effect of methylprednisolone on the oxidative burst activity, adhesion molecules and clinical outcome following open heart surgery. Scand Cardiovasc J 1997; 31: 283–8PubMedGoogle Scholar
  59. 59.
    Toledo-Pereyra LH, Lin CY, Kundler H, et al. Steroids in heart surgery: a clinical double-blind and randomized study. Am Surg 1980; 46: 155–60PubMedGoogle Scholar
  60. 60.
    Rao G, King J, Ford W, et al. The effects of methylprednisolone on the complications of coronary artery surgery. Vasc Surg 1977; 11: 1–7PubMedGoogle Scholar
  61. 61.
    Wan S, LeClerc JL, Schmartz D, et al. Hepatic release of interleukin-10 during cardiopulmonary bypass in steroid-pretreated patients. Am Heart J 1997; 133: 335–9PubMedGoogle Scholar
  62. 62.
    Wan S, LeClerc JL, Huynh CH, et al. Does steroid pretreatment increase endotoxin release during clinical cardiopulmonary bypass? J Thorac Cardiovasc Surg 1999; 117: 1004–8PubMedGoogle Scholar
  63. 63.
    Alho A, Saikku K, Eerola P, et al. Corticosteroids in patients with a high risk of fat embolism syndrome. Surg Gynecol Obstet 1978; 147: 358–62PubMedGoogle Scholar
  64. 64.
    Lepistö P, Avikainen V, Alho A, et al. Fat embolism in severely injured patients. Ann Chir Gynaecol Fenn 1975; 64: 198–202PubMedGoogle Scholar
  65. 65.
    Lindeque BGP, Schoeman HS, Dommisse GF, et al. Fat embolism and the fat embolism syndrome. A double-blind therapeutic study. J Bone Joint Surg Br 1987; 69: 128–31PubMedGoogle Scholar
  66. 66.
    Schonfeld SA, Ploysongsang Y, DiLisio R, et al. Fat embolism prophylaxis with corticosteroids. Aprospective study in high-risk patients. Ann Intern Med 1983; 99: 438–43PubMedGoogle Scholar
  67. 67.
    Stoltenberg JJ, Gustilo RB. The use of methylprednisolone and hypertonic glucose in the prophylaxis of fat embolism syndrome. Clin Orthop 1979; 143: 211–21PubMedGoogle Scholar
  68. 68.
    Svennevig JL, Bugge-Asperheim B, Vaage J, et al. Corticosteroids in the treatment of blunt injury of the chest. Injury 1984; 16: 80–4PubMedGoogle Scholar
  69. 69.
    Svennevig JL, Bugge-Asperheim B, Geiran O, et al. High-dose corticosteroids in thoracic trauma. Acta Chir Scand Suppl 1985; 526: 110–9PubMedGoogle Scholar
  70. 70.
    Svennevig JL, Bugge-Asperheim B, Birkeland S, et al. Efficacy of steroids in the treatment of lung contusion. Acta Chir Scand Suppl 1980; 499: 87–92PubMedGoogle Scholar
  71. 71.
    Mikawa K, Ikegaki J, Maekawa N, et al. Perioperative effect of methylprednisolone given during lung surgery on plasma concentrations of C3a and C5a. Scand J Thorac Cardiovasc Surg 1990; 24: 229–33PubMedGoogle Scholar
  72. 72.
    Edfeldt H, Thomson D. Early hemodynamic and respiratory changes following tourniquet release - influence of large doses of methylprednisolone. Acta Chir Scand Suppl 1980; 499: 45–55PubMedGoogle Scholar
  73. 73.
    Boscoe MJ, Yewdall VM, Thompson MA, et al. Complement activation during cardiopulmonary bypass: quantitative study of effects of methylprednisolone and pulsatile flow. BMJ 1983; 287: 1747–50PubMedGoogle Scholar
  74. 74.
    Diego RP, Mihalakakos PJ, Hexum TD, et al. Methylprednisolone and full-dose aprotinin reduce reperfusion injury after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997; 11: 29–31PubMedGoogle Scholar
  75. 75.
    Enderby DH, Boylett A, Parker DJ. Methyl prednisolone and lung function after cardiopulmonary bypass. Thorax 1979; 34: 720–5PubMedGoogle Scholar
  76. 76.
    Ferries LH, Marx Jr JJ, Ray III JF. The effect of methylprednisolone on complement activation during cardiopulmonary bypass. J Extracorp Technol 1984; 16: 83–8Google Scholar
  77. 77.
    Fosse E, Mollnes TE, Østerud A, et al. Effects of methylprednisolone on complement activation and leukocyte counts during cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg 1987; 21: 255–61PubMedGoogle Scholar
  78. 78.
    Hill GE, Alonso A, Thiele GM, et al. Glucocorticoids blunt neutrophil CD11b surface glycoprotein upregulation during cardiopulmonary bypass in humans. Anesth Analg 1994; 79: 23–7PubMedGoogle Scholar
  79. 79.
    Hill GE, Alonso A, Spurzem JR, et al. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 1995; 110: 1658–62PubMedGoogle Scholar
  80. 80.
    Jorens PG, De Jongh R, De Backer W, et al. Interleukin-8 production in patients undergoing cardiopulmonary bypass. The influence of pretreatment with methylprednisolone. Am Rev Respir Dis 1993; 148: 890–5PubMedGoogle Scholar
  81. 81.
    Karlstad MD, Patteson SK, Guszcza JA, et al. Methylprednisolone does not influence endotoxin translocation during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1993; 7: 23–7PubMedGoogle Scholar
  82. 82.
    Kawamura T, Inada K, Nara N, et al. Influence of methylprednisolone on cytokine balance during cardiac surgery. Crit Care Med 1999; 27: 545–8PubMedGoogle Scholar
  83. 83.
    Kawamura T, Inada K, Okada H, et al. Methylprednisolone inhibits increase of interleukin 8 and 6 during open heart surgery. Can J Anaesth 1995; 42: 399–403PubMedGoogle Scholar
  84. 84.
    Kobayashi N. The circulatory and respiratory effects of methylprednisolone associated with catecholamine undergoing open heart surgery [In Japanese]. Tokyo Joshi Ikadaigaku Zasshi [Journal of Tokyo Womens Medical College] 1996; 66: 1–10Google Scholar
  85. 85.
    Loubser PG, Yawn D. Effects of methylprednisolone on complement activation during cardiopulmonary bypass and following protamine administration [abstract]. Anesthesiology 1994; 81: A173Google Scholar
  86. 86.
    Loubser PG. Effect of methylprednisolone on complement activation during heparin neutralization. J Cardiovasc Pharmacol 1997; 29: 23–7PubMedGoogle Scholar
  87. 87.
    Tabardel Y, Duchateau J, Schmartz D, et al. Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. Surgery 1996; 119: 76–80PubMedGoogle Scholar
  88. 88.
    Thompson MA, Broadbent MP. Methylprednisolone prior to cardiopulmonary bypass. Anaesthesia 1980; 35: 345–53PubMedGoogle Scholar
  89. 89.
    Thompson MA, Broadbent MP, English J. Plasma levels of methylprednisolone following administration during cardiac surgery. Anaesthesia 1982; 37: 405–7PubMedGoogle Scholar
  90. 90.
    Deeks J, Bradburn M, Localio R, et al. Much ado about nothing: statistical methods for meta-analysis with rare events [abstract]. 2nd Symposium on Systematic Reviews. 1999 Jan 8-9; Oxford, 31Google Scholar
  91. 91.
    Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310: 452–4PubMedGoogle Scholar
  92. 92.
    Dernek S, Tünerir B, Sevin B, et al. The effects of methylprednisolone on complement, immunoglobulins and pulmonary neutrophil sequestration during cardiopulmonary bypass. Cardiovasc Surg 1999; 7: 414–8PubMedGoogle Scholar
  93. 93.
    Shimada M, Saitoh A, Kano T, et al. The effect of a perioperative steroid pulse on surgical stress in hepatic resection. Int Surg 1996; 81: 49–51PubMedGoogle Scholar
  94. 94.
    Teoh KH, Bradley CA, Gauldie J, et al. Steroid inhibition of cytokine-mediated vasodilation after warm heart surgery. Circulation 1995; 92 Supple. 2: S347–S353Google Scholar
  95. 95.
    van der Merwe CJ, Louw AF, Welthagen D, et al. Adult respiratory distress syndrome in cases of severe trauma-the prophylactic value of methylprednisolone sodium succinate. S Afr Med J 1985; 67: 279–84PubMedGoogle Scholar
  96. 96.
    Lee CW, Chae JK, Lim HY, et al. Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation. Am Heart J 1999; 138: 60–3PubMedGoogle Scholar
  97. 97.
    Pepine CJ, Hirshfeld JW, Macdonald RG, et al. Acontrolled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group. Circulation 1990; 81: 1753–61PubMedGoogle Scholar
  98. 98.
    Flood TR, McManners J, El-Attar A, et al. Randomized prospective study of the influence of steroids on postoperative eyeopening after exploration of the orbital floor. Br J Oral Maxillofac Surg 1999; 37: 312–5PubMedGoogle Scholar
  99. 99.
    Holland CS. The influence of methylprednislone on post-operative swelling following oral surgery. Br J Oral Maxillofac Surg 1987; 25: 293–9PubMedGoogle Scholar
  100. 100.
    Butler J, Pathi VL, Paton RD, et al. Acute-phase responses to cardiopulmonary bypass in children weighing less than 10 kilograms. Ann Thorac Surg 1996; 62: 538–42PubMedGoogle Scholar
  101. 101.
    Westfall SH, Stephens C, Kesler K, et al. Complement activation during prolonged extracorporeal membrane oxygenation. Surgery 1991; 110: 887–91PubMedGoogle Scholar
  102. 102.
    Kallenbach J, Lewis M, Zaltzman M, et al. ’Low-dose’ corticosteroid prophylaxis against fat embolism. J Trauma 1987; 27: 1173–6PubMedGoogle Scholar
  103. 103.
    Matsutani T, Onda M, Sasajima K, et al. Glucocorticoid attenuates a decrease of antithrombin III following major surgery. J Surg Res 1998; 79: 158–63PubMedGoogle Scholar
  104. 104.
    Rendina EA, Venuta F, Ricci C. Effects of low-dose steroids on bronchial healing after sleeve resection. A clinical study. J Thorac Cardiovasc Surg 1992; 104: 888–91PubMedGoogle Scholar
  105. 105.
    Peillon D, Dubost J, Roche C, et al. Effect of corticosteroids and haemodilution on postoperative inflammation after maxillofacial surgery. Ann Fr Anesth Reanim 1996; 15: 157–61PubMedGoogle Scholar
  106. 106.
    Owsley JQ, Weibel TJ, Adams WA. Does steroid medication reduce facial edema following face lift surgery? A prospective, randomized study of 30 consecutive patients. Plast Reconstr Surg 1996; 98: 1–6PubMedGoogle Scholar
  107. 107.
    Marion DW, Jannetta PJ. Use of perioperative steroids with microvascular decompression operations. Neurosurgery 1988; 22: 353–7PubMedGoogle Scholar
  108. 108.
    Williams PM, Strome M, Eliachar I, et al. Impact of steroids on recovery after uvulopalatopharyngoplasty. Laryngoscope 1999; 109: 1941–6PubMedGoogle Scholar
  109. 109.
    Bouillon B, Kramer M, Schafer U, et al. High dose corticosteroids in patients with multiple trauma [abstract]. Shock 1996; 5Suppl. 2: S45Google Scholar
  110. 110.
    Muñoz C, Conejero R, Caturla J, et al. Inhibition of cytokine production in cardiopulmonary bypass [abstract]. Clin Intens Care 1992; 3 Suppl.: S52Google Scholar
  111. 111.
    Schulze S, Sommer P, Bigler D, et al. Effect of combined prednisolone, epidural analgesia, and indomethacin on the systemic response after colonic surgery. Arch Surg 1992; 127: 325–31PubMedGoogle Scholar
  112. 112.
    Vallejo JL, Gimenez-Fernandez R, Mainer JL, et al. Análisis clínico del efecto protector de la metil-prednisolona sobre el corazón en paro anoxico (estudio randomizado). Rev Esp Cardiol 1977; 30: 705–9PubMedGoogle Scholar
  113. 113.
    Fu ZX, Nagelschmidt M, Saad S, et al. Improved outcome by preoperative administration of methylprednisolone before large abdominal surgery interventions-a prospective double-blind study [in German]. Langenbecks Arch Chir Suppl Kongressbd 1997; 114: 663–6Google Scholar
  114. 114.
    Derendorf H, Mollmann H, Krieg M, et al. Pharmacodynamics of methylprednisolone phosphate after single intravenous administration to healthy volunteers. Pharm Res 1991; 8: 263–8PubMedGoogle Scholar
  115. 115.
    Novak E, Stubbs SS, Seckman CE, et al. Effects of a single large intravenous dose of methylprednisolone sodium succinate. Clin Pharmacol Ther 1970; 11: 711–7PubMedGoogle Scholar
  116. 116.
    Eypasch E, Lefering R, Kum CK, et al. Probability of adverse events that have not yet occurred: a statistical reminder. BMJ 1995; 311: 619–20PubMedGoogle Scholar
  117. 117.
    Conn HO, Blitzer BL. Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med 1976; 294: 473–9PubMedGoogle Scholar
  118. 118.
    McIntyre PB, Berkey CS, King SM, et al. Dexamethasone as adjunctive therapy in bacterial meningitis. Ameta-analysis of randomized clinical trials since 1988. JAMA 1997; 278: 925–31PubMedGoogle Scholar
  119. 119.
    Dumouchel W. Meta-analysis for dose-response models. Stat Med 1995; 14: 679–85PubMedGoogle Scholar
  120. 120.
    DeMaria EJ, Reichman W, Kenney PR, et al. Septic complications of corticosteroid administration after central nervous system trauma. Ann Surg 1985; 202: 248–52PubMedGoogle Scholar
  121. 121.
    Galandiuk S, Raque G, Appel S, et al. The two-edged sword of large-dose steroids for spinal cord trauma. Ann Surg 1993; 218: 419–27PubMedGoogle Scholar
  122. 122.
    Gerndt SJ, Rodriguez JL, Pawlik JW, et al. Consequences of high-dose steroid therapy for acute spinal cord injury. J Trauma 1997; 42: 279–84PubMedGoogle Scholar
  123. 123.
    Kunz R, Oxman AD. The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. BMJ 1998; 317: 1185–90PubMedGoogle Scholar
  124. 124.
    Bocanegra TS, Castañeda MO, Espinoza LR, et al. Sudden death after methylprednisolone pulse therapy [letter]. Ann Intern Med 1981; 95: 122PubMedGoogle Scholar
  125. 125.
    Moses RE, McCormick A, Nickey W. Fatal arrhythmia after pulse methylprednisolone therapy. Ann Intern Med 1981; 95: 781–2PubMedGoogle Scholar
  126. 126.
    Guillen EL, Ruiz AM, Bugallo JB. Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient [letter]. Am J Kidney Dis 1998; 32: E4PubMedGoogle Scholar
  127. 127.
    Tvede N, Nielsen LP, Andersen V. Bradycardia after high-dose intravenous methylprednisolone therapy. Scand J Rheumatol 1986; 15: 302–4PubMedGoogle Scholar
  128. 128.
    Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord 1983; 5: 319–32PubMedGoogle Scholar
  129. 129.
    Olsen R, Lindberg C, Anderson O. Centrolobular liver cell necrosis, myocardial infarction, and hyperamylasaemia after high dose corticosteroids [letter]. BMJ 1994; 308: 454Google Scholar
  130. 130.
    Smith RS, Warren DJ. Effects of high-dose intravenous methylprednisolone on circulation in humans. Transplantation 1983; 35: 349–51PubMedGoogle Scholar
  131. 131.
    Schonwald S. Methylprednisolone anaphylaxis. Am J Emerg Med 1999; 17: 583–5PubMedGoogle Scholar
  132. 132.
    Schulz KF, Chalmers I, Hayes RH, et al. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408–12PubMedGoogle Scholar
  133. 133.
    Plihal W, Krug R, Pietrowsky R, et al. Corticosteroid receptor mediated effects on mood in humans. Psychoneuroendo-crinology 1996; 21: 515–23PubMedGoogle Scholar
  134. 134.
    Patten SB, Neutel SI. Corticosteroid-induced adverse psychiatric effects: incidence, diagnosis and management. Drug Saf 2000; 22: 111–22PubMedGoogle Scholar
  135. 135.
    Felson DT, Anderson JJ. Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet 1987; I: 902–6Google Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  • Stefan Sauerland
    • 1
  • Manfred Nagelschmidt
    • 1
  • Peter Mallmann
    • 2
  • Edmund A. M. Neugebauer
    • 1
  1. 1.Biochemical and Experimental Division, 2nd Department of SurgeryUniversity of CologneCologneGermany
  2. 2.Department of Gynaecology and ObstetricsUniversity of CologneCologneGermany

Personalised recommendations